Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

OBJECTIVE: Abatacept is a biological disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) and modulates the costimulatory signal by cluster of differentiation (CD)28:CD80/CD86 interaction required for T cell activation. Since CD28-mediated signalling regul...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:RMD Open
Autors principals: Ghannam, Khetam, Martinez Gamboa, Lorena, Kedor, Claudia, Spengler, Lydia, Kuckelkorn, Ulrike, Häupl, Thomas, Burmester, Gerd, Feist, Eugen
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7547540/
https://ncbi.nlm.nih.gov/pubmed/32998980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001248
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars